Both medications are designed to complement a comprehensive weight management plan, including diet, exercise, and behavioral modifications
Accordingly, people with type 2 diabetes, cardiovascular disease, heart failure, or chronic kidney disease should be treated appropriately with an SGLT-2 inhibitor or GLP-1RA, even because more adults with type 2 diabetes in the US have suboptimal glycemic control now compared to 10 years ago, associated with a resurgence in vascular diabetic complications [32]
53.9% achieved 5% weight loss with AOM Equally crucial to total weight loss percentage is the proportion of patients achieving clinically meaningful outcomes
After all my research, I havent sworn off GLP-1s foreverbut for now theyre a no for me
While patients in Naltrexone group had lower rate of comorbid conditions, the difference was balanced in PS-matched groups